UniQure reach­es mile­stone, Idor­si­a's bridge fi­nanc­ing ex­tends run­way, and Phar­varis scores $70M place­ment

UniQure, the de­vel­op­er of Hem­genix, the $3.5 mil­lion he­mo­phil­ia B gene ther­a­py li­censed to Aus­tralia’s CSL Behring, an­nounced Tues­day morn­ing that it hit a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER